An Atypical Autoinflammatory Disease Due to an LRR Domain NLRP3 Mutation Enhancing Binding to NEK7 by Caseley, EA et al.
Vol.:(0123456789) 
Journal of Clinical Immunology 
https://doi.org/10.1007/s10875-021-01161-w
ORIGINAL ARTICLE
An Atypical Autoinflammatory Disease Due to an LRR Domain NLRP3 
Mutation Enhancing Binding to NEK7
Emily A. Caseley1 · Samuel Lara‑Reyna2 · James A. Poulter1 · Joanne Topping1 · Clive Carter3 · Fatima Nadat3 · 
Gavin P. Spickett4 · Sinisa Savic1,5,6 · Michael F. McDermott1
Received: 24 May 2021 / Accepted: 15 October 2021 
© The Author(s) 2021
Abstract
The NLRP3 inflammasome is a vital mediator of innate immune responses. There are numerous NLRP3 mutations that cause 
NLRP3-associated autoinflammatory diseases (NLRP3-AIDs), mostly in or around the NACHT domain. Here, we present a 
patient with a rare leucine-rich repeat (LRR) domain mutation, p.Arg920Gln (p.R920Q), associated with an atypical NLRP3-
AID with recurrent episodes of sore throat and extensive oropharyngeal ulceration. Unlike previously reported patients, who 
responded well to anakinra, her oral ulcers did not significantly improve until the PDE4 inhibitor, apremilast, was added to 
her treatment regimen. Here, we show that this mutation enhances interactions between NLRP3 and its endogenous inhibitor, 
NIMA-related kinase 7 (NEK7), by affecting charge complementarity between the two proteins. We also demonstrate that 
additional inflammatory mediators, including the NF-кB and IL-17 signalling pathways and IL-8 chemokine, are upregulated 
in the patient’s macrophages and may be directly involved in disease pathogenesis. These results highlight the role of the 
NLRP3 LRR domain in NLRP3-AIDs and demonstrate that the p.R920Q mutation can cause diverse phenotypes between 
families.
Keywords NLRP3 inflammasome · NLRP3-associated autoinflammatory diseases · Leucine-rich repeat domain · 
Inflammation · NIMA-related kinase 7
Introduction
NLRP3 is an integral part of the NLRP3 inflammasome, a 
large cytosolic protein complex which acts as an intracellu-
lar innate immune sensor. NLRP3 inflammasome assembly 
occurs following the detection of a wide range of harmful 
stimuli and mediates caspase-1 autoproteolysis and activa-
tion, leading to caspase-1-mediated cleavage of the pro-
inflammatory cytokines, IL-1β and IL-18, into their active 
forms, and cleavage of gasdermin-D, which subsequently 
forms membrane pores and induces pyroptotic cell death. 
Gain-of-function mutations in NLRP3 are associated with a 
series of rare autoinflammatory diseases (AIDs), collectively 
known as NLRP3-associated autoinflammatory diseases 
(NLRP3-AIDs), previously referred to as cryopyrin-associ-
ated periodic syndromes (CAPS) [1]. NLRP3-AIDs are typi-
fied by recurrent episodes of fever, urticaria, arthralgia, and 
chronic inflammation which can lead to long-term damage 
including sensorineural hearing loss and amyloidosis [2].
The NLRP3 protein comprises three domains: the pyrin 
domain (PYD), the central NACHT domain, and the leucine-
rich repeat (LRR) domain. Most of the reported NLRP3-
AID-related NLRP3 mutations are located in or around the 
central NACHT domain [3], whereas the C terminus LRR 
domain, the function of which is unclear due to evidence that 
it is dispensable for NLRP3 inflammasome activation [4], is 
an uncommon site for pathogenic mutations [3]. One of the 
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few validated LRR domain mutations is the missense sub-
stitution c.2759G > A, coding for p.Arg920Gln (p.R920Q) 
in the LRR domain. This mutation was previously reported 
in two unrelated North American families, where it was 
previously known as p.Arg918Gln (p.R918Q) and primar-
ily caused autosomal-dominant sensorineural hearing loss 
[5] which is common in NLRP3-AIDs [6]. However, the 
symptoms observed in these families were varied; one fam-
ily reported hearing loss with an age of onset in the second 
to fourth decade of life, with no additional physical signs 
or symptoms of NLRP3-AID. In contrast, the second fam-
ily experienced hearing loss in the first 10 years which was 
accompanied by autoinflammatory signs and symptoms, 
including oral ulcers, without serologic signs of inflamma-
tion, contributing to an atypical NLRP3-AID phenotype [5]. 
Hearing loss and autoinflammatory symptoms were gener-
ally reversed or improved following treatment with the inter-
leukin-1 (IL-1) receptor antagonist anakinra, which has been 
historically used in the treatment of NLRP3-AIDs [7–9]. 
Here, we present another case of a patient with the NLRP3-
p.R920Q mutation. This patient’s symptoms spanned the 
spectrum of those seen in this previous study; she experi-
enced mild hearing loss (only evident on audiogram) with 
some evidence of systemic inflammation, but her main com-
plaint was persistent oropharyngeal ulcers. She showed only 
a partial response to anakinra, instead responding well to 
steroids and the phosphodiesterase type-4 (PDE4) inhibitor 
apremilast.
In this report, we investigated this atypical patient phe-
notype, the potential pathogenic mechanisms of this LRR 
domain mutation and signalling pathways which contrib-
ute to the disease. Altogether, our study provides a detailed 
exploration of this rare pathogenic mutation.
Methods
Human Subjects
Work using human samples was approved by the Health 
Research Authority (study number 18/YH/0070). Informed 
written consent was obtained from participants prior to sam-
ple collection. Age- and sex-matched HCs were recruited 
from St James’s University Hospital, Leeds, UK.
Samples
Patient and HC samples were collected in VACUETTE® 
tubes (Greiner Bio-One), coated with EDTA anticoagulant 
or serum clot activator gel for whole blood or serum, respec-
tively. Serum samples were collected by allowing the sample 
to clot for 1 h, followed by centrifugation at 1000 × g for 
15 min.
Sequencing
The coding sequence was captured from genomic DNA 
using the SureSelectXT target enrichment kit with All Exon 
v5 capture library (Agilent). Sequencing was performed 
on a HiSeq 3000 (Illumina) using a 2 × 150-bp paired-end 
sequencing protocol, and analysis restricted to the auto-
inflammatory/autoimmune gene panel (supplementary 
methods).
Cell Culture and Stimulation
HEK293T cells (ATCC) were cultured according to the 
manufacturer’s specifications. Monocytes were isolated 
from whole blood using Lymphoprep density gradient media 
(StemCell), as outlined in the supplementary methods. The 
NLRP3 inflammasome was stimulated with 10 ng/mL LPS 
(Ultrapure Escherichia coli K12, Invivogen) for 4 h, with 
5 mM ATP (Invivogen) added for the last 30 min. After 
stimulation, cells were lysed with TRIzol (Invitrogen).
Cytokine Quantification by ELISA
Release of IL-1β, IL-18, TNF, IL-6, or IL-10 in patient sera 
or media from cultured cells was detected by enzyme-linked 
immunosorbent assay (ELISA). Nunc MaxiSorp 96-well 
plates (Thermo Fisher Scientific) and commercially avail-
able ELISA kits were used (Thermo Fisher Scientific, prod-
uct codes listed in supplementary methods) according to the 
manufacturer’s specifications.
ASC Speck Quantification by Flow Cytometry
A 2 μL of PE-conjugated ASC antibody (HASC-71 clone, 
BioLegend) was added to 100 μL of cell culture media, and 
the mixture incubated in FACS collection tubes on a shaker 
for 1 h. Size gating was carried out with Megamix-Plus 
beads (Biocytex) according to the manufacturer’s specifica-
tions and was used to threshold out readings below 0.9 μm 
(representative flow cytometry plots shown in supplemen-
tary methods). Samples were run and analysed on a Cyto-
FLEX-S (Beckman Coulter).
Gene Expression Analysis
RNA isolation was carried out using TRIzol Reagent and 
Phasemaker tubes (Thermo Fisher Scientific) according to 
the manufacturer’s specifications. One hundred nanograms 
of RNA was converted to cDNA using the SuperScript IV 
one-step RT-PCR system (Invitrogen) according to the 
manufacturer’s specifications. Gene expression was analysed 
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using TaqMan probes (Thermo Fisher Scientific); the sup-
plementary methods detail the probes and cycle parameters 
used. Data were expressed as relative expression compared 
to the housekeeping genes, ACTB and HPRT1.
RNA Preparation and RNAseq
RNA was isolated using TRIzol (Invitrogen) and Phase-
maker tubes (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. RNA quality was assessed 
using an Agilent 4200 TapeStation (Agilent Technologies). 
Library preparation and RNA-seq was carried out on a high-
throughput Illumina platform and paired-end reads gener-
ated (Novogene (UK) Company Limited); further informa-
tion is provided in the supplementary methods.
In Silico Investigation
The cryo-EM structure of NLRP3 in complex with NEK7 
(PDB 6NPY)[10] was used for structural investigations. 
Interaction analysis was conducted using PISA [11] and 
structure representations, including electrostatic surface 
representations, produced using Pymol version 2.3.3 [12].
Immunoprecipitation Studies
Cells were transfected with 10 μg of plasmids for NLRP3-
GFP and/or NEK7-His (details in supplementary methods) 
using Opti-MEM and Lipofectamine 2000 (Thermo Fisher 
Scientific) according to the manufacturer’s specifications. 
Cell lysates were harvested and used for immunoprecipita-
tion, then analysed by SDS-PAGE and Western blot.
Statistical Analysis
Data were presented as the mean ± standard error of the 
mean (SEM). Analyses were performed using GraphPad 
Prism 9. A two-way ANOVA test with Tukey’s post-hoc 
analysis was performed when calculating variance between 
samples (p values *p < 0.05, **p < 0.01, ***p < 0.001). 
p < 0.05 was considered significant.
Results
Case Presentation
This female patient presented at the age of 9 years mainly 
with recurrent episodes of sore throat and associated 
extensive oropharyngeal ulceration. She also reported epi-
sodic fevers but without any clear pattern. Other reported 
problems included recurrent chest infections treated with 
antibiotics, painful joints (particularly knees and hands), 
headaches associated with sickness and vomiting, and epi-
sodes of periorbital cellulitis. There was no history of geni-
tal ulceration, other skin rashes, unexplained abdominal or 
chest pains or previous thromboembolic events. She did not 
report any hearing difficulties. Prior to the genetic diagnosis, 
there was no overt family history of similar problems. She 
was extensively investigated, and her immunological workup 
showed a normal immunoglobulin and lymphocyte profile. 
Tests of her lymphocyte and neutrophil function also showed 
no obvious abnormalities. The only positive finding was a 
non-specific speckled anti-nuclear antibody test, but she had 
no other clinical features for a diagnosis of connective tissue 
disease. She did not meet the diagnostic criteria for Behcet’s 
disease, and she was HLA-B51 negative. Interestingly, the 
systemic inflammatory marker, C-reactive protein, was not 
always elevated during acute flairs. Over the 15 years fol-
lowing her initial presentation, she continued to be symp-
tomatic despite numerous trials of different treatments. She 
responded well to corticosteroids, which controlled her oro-
pharyngeal ulceration, but did not benefit from colchicine, 
hydroxychloroquine, azathioprine, methotrexate, infliximab, 
tocilizumab or baricitinib. She had a trial of anakinra (up 
to 200 mg daily), which helped with fevers, and to some 
extent headaches and arthralgia, but had no effect on the 
mucosal ulceration. Finally, apremilast was added to her 
anakinra regimen, and this combination led to significantly 
better symptomatic control with gradual tapering and even-
tual discontinuation of corticosteroids. She subsequently 
became pregnant which necessitated withdrawal of apre-
milast since this medication is not licenced in pregnancy. 
Consequently, she relapsed with oropharyngeal ulceration 
becoming troublesome and requiring reintroduction of high-
dose prednisolone.
The Inflammatory Phenotype Is Associated 
with an LRR Domain NLRP3 R920Q Mutation
The patient consented to genetic testing, and exome sequenc-
ing of the patient’s genomic DNA was undertaken; vari-
ants in a panel of 49 autoinflammatory/autoimmune disease 
genes were analysed (see Methods). A variant in NLRP3 
was identified, c.2759G > A which is predicted to cause the 
missense substitution p.Arg920Gln (p.R920Q) (Fig. 1a), 
which is located in the LRR domain of NLRP3 (Fig. 1b). 
The variant has a CADD score of 21.5 (v1.6), is not present 
in approximately 125,000 exomes available in the Genome 
Aggregation Database (accessed 07.01.21)[13], and has only 
previously been reported in two unrelated North Ameri-
can families who presented with hearing loss and mixed 
symptoms of systemic autoinflammation [5]. An autosomal 
dominant inheritance pattern was also observed in these 
prior cases, and targeted sequencing of our patient’s parents 
indicated that the p.R920Q mutation was inherited from her 
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father, who also had a history of hearing loss (Fig. 1a, c). No 
systemic inflammation was reported by the patient’s father, 
although limited information about him was available. The 
patient experienced hearing loss, although this was mild to 
the extent that she did not report it and it only became appar-
ent in the audiogram (Fig. 1d).
Heightened Inflammatory Responses in Primary 
Cells from the Patient
The NLRP3 inflammasome is primarily expressed by mye-
loid cells [14]; thus, we assessed the patient’s monocyte 
responses to canonical NLRP3 inflammasome stimula-
tion in vitro using lipopolysaccharide (LPS) and extracel-
lular ATP. Basal IL-1β levels were significantly elevated 
compared to healthy control (HCs), and stimulation by 
LPS alone caused significantly higher IL-1β release from 
patient monocytes compared to HCs, which is indicative 
of an NLRP3-AID [15] (Fig. 2a). In contrast, there was no 
notable difference in maximal IL-1β release from patient 
and HC monocytes in response to LPS and ATP stimula-
tion, although patient monocytes stimulated for the NLRP3 
inflammasome released significantly higher levels of IL-18 
compared to HCs. Il1b gene expression was also higher 
in patient’s monocytes compared to HCs when unstimu-
lated or stimulated with LPS only, but not with LPS and 
ATP (Fig. S1a). Like IL-1β, IL-6 release from the patient’s 
monocytes in response to LPS stimulation alone was ele-
vated compared to HCs, albeit not significantly, whereas 
release of another proinflammatory cytokine which is not 
directly regulated by the NLRP3 inflammasome, TNF, was 
similar between patients’ and HC monocytes under all con-
ditions. In contrast, the anti-inflammatory cytokine IL-10 
was significantly elevated following stimulation with LPS 
alone (Fig. 2a). In contrast, TNF release from the patient’s 
M1 macrophages was significantly higher than from HCs 
Fig. 1  The autosomal dominant 
p.R920Q NLRP3 mutation is 
associated with an enhanced 
inflammatory phenotype. 
a Sequence chromatogram 
showing the wild-type NLRP3 
sequence (top) and the 
c.2759G > A transition, lead-
ing to the p.R920Q mutation 
in the patient and patient’s 
father as indicated (bottom). 
b A 3D representation of the 
NLRP3 structure in complex 
with its regulator NEK7, with 
the pyrin domain and N-lobe 
omitted from NLRP3 and 
NEK7, respectively. Domains 
are colour coded as shown in 
the 2D representation, with 
domains omitted from the 
structures shown in grey. The 
R920 residue is circled in black. 
c p.R920Q inheritance and fam-
ily phenotype, hearing loss and 
periodic fevers. d The patient’s 
audiogram showing mild hear-
ing loss
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(Fig. S1b). Amplified NLRP3-mediated cytokine release has 
been associated with an increase in the formation of ASC 
specks, micrometre-sized structures formed by the adap-
tor protein ASC (apoptosis-associated speck-like protein 
containing a CARD) [16–19]. Significantly higher levels of 
extracellular ASC specks were detected in cell culture media 
from unstimulated or LPS and ATP-stimulated patient’s 
monocytes compared to HCs, suggesting that this mutation 
allows the NLRP3 inflammasome complex to form more 
readily (Fig. 2b). In contrast to cell supernatants, determi-
nation of circulating cytokine levels in the patient’s serum 
showed no significant difference in IL-1β, IL-18, TNF or 
IL-10 levels compared to HC serum. However, IL-6 was 
significantly raised in the patient’s serum (Fig. 2c), as previ-
ously observed in different NLRP3-AIDs [8, 20, 21].
The NLRP3 p.R920Q Mutation Enhances 
NLRP3‑NEK7 Interactions
Our initial assays support previous reports of p.R920Q 
being a pathogenic NLRP3 mutation [22, 23]. To explore the 
mechanism(s) whereby this mutation affects NLRP3 inflam-
masome function, we interrogated the recently determined 
cryo-electron microscopy (cryo-EM) structure of NLRP3 
in complex with NEK7 [10]. Residue 920 lies in the LRR 
domain at the NLRP3/NEK7 interface (Fig. 1b), and previ-
ously reported LRR domain mutations affect specific inter-
actions between NLRP3 and NEK7 [24–26]; we therefore 
investigated the effects of the p.R920Q mutation on NLRP3/
NEK7 interactions.
Interactions between NLRP3 and NEK7 are determined 
in part by charge complementarity; the calculated isoelectric 
points (pIs) of NEK7 and NLRP3 are 8.5 and 6.2, respec-
tively, indicating an overall positive charge for NEK7 and 
overall negative charge for NLRP3 at a physiological pH 
[10]. However, there is a cluster of positive charge density in 
the NLRP3 LRR domain at the interface with NEK7 in the 
region of R920 (Fig. 3a). In silico mutation of this residue to 
glutamine was predicted to reduce this net positive charge, 
thereby increasing the electrostatic interactions between the 
LRR domain and the positively charged NLRP3-interacting 
surface of NEK7 (Fig. 3a).
Important residues in NEK7 involved in interactions with 
the NLRP3 LRR domain in the immediate vicinity of R920, 
as assessed by PISA [11], included R121, K124, H125, K128 
and Q129 (Fig. 3b). The p.R920Q mutation was predicted 
to impact the local confirmation of residues, increasing the 
buried surface area of K124 by 10% and decreasing that of 
K128 by 10%, respectively, in addition to increasing the pre-
dicted interface stability of the complex [11]. These in silico 
observations were further interrogated with co-immuno-
precipitation experiments using HEK293T cells transfected 
with WT NLRP3, or NLRP3 with the p.R920Q or the previ-
ously described p.D946G mutation, which reduces NLRP3/
NEK7 interactions [26]. Introduction of the p.D946G muta-
tion reduced the amount of NEK7, pulled down by NLRP3 
compared to the WT protein, whereas NLRP3 harbouring 
the p.R920Q substitution showed increased binding to NEK7 
compared to WT-NLRP3 (Fig. 3c and Fig. S2). Additionally, 
NLRP3 transfected into HEK293T cells was pulled down 
Fig. 2  The NLRP3 p.R920Q mutation leads to a NLRP3-AID 
cytokine release profile. a Cytokine profile of patient’s primary 
monocytes when unstimulated, stimulated with LPS alone or with 
LPS and ATP for NLRP3 inflammasome activation, compared to 3 
healthy controls (HCs). b Extracellular ASC speck levels detected 
by flow cytometry in cell media supernatants from patients’ or HC 
monocytes which were unstimulated, stimulated with LPS alone or 
stimulated with both LPS and nigericin for NLRP3 inflammasome 
activation c. Cytokine levels in patient and HC serum. Data shown 
is compiled from 3 independent experiments and is presented as 
mean ± SEM, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001
 Journal of Clinical Immunology
1 3
Fig. 3  The p.R920Q mutation in the NLRP3 protein enhances 
NLRP3-NEK7 interactions. a Electrostatic surface representation 
of WT NLRP3 (left), NLRP3 with the p.R920Q mutation (centre) 
and NEK7 (right); electrostatic potential is coloured to show nega-
tive charge (− 5.0 kT  e−1) in red and positive charge (5.0 kT  e−1) in 
blue, and black arrows show the change in charge density resulting 
from the p.R920Q mutation. Black boxes outline interacting domains. 
b Magnified view of the interface between NLRP3 (orange) and 
NEK7 (red) surrounding residue 920. The main chains are shown as 
cartoons and potentially interacting side chains as sticks. c NLRP3-
NEK7 association analysed by immunoprecipitation and immunob-
lot in lysates of HEK293T cells transfected with His-tagged NEK7 
alone, or co-transfected with WT NLRP3 or NLRP3 containing the 
p.D926G or p.R920Q mutations. Representative blots are shown 
of three separate experiments; replicates are shown in Fig.  S2. d 
NLRP3-NEK7 association analysed by immunoprecipitation and 
immunoblot in lysates of HEK293T cells expressing endogenous 
NEK7 and transfected with either WT or mutant NLRP3 as indicated; 
replicates are shown in Fig.  S3. e Immunoprecipitation and immu-
noblot assays in lysates of HEK293T cells co-transfected with WT 
or p.R920Q-NLRP3 with increasing concentrations of His-tagged 
NEK7; 25%, 50% or 100% as indicated; replicates are shown in 
Fig. S4. Immunoprecipitation and immunoblot assays were repeated 
3 times in each instance
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by the endogenously expressed NEK7 [26, 27]. These co-
immunoprecipitation experiments further demonstrated that 
NLRP3 with a p.D946G mutation reduced the amount of 
NLRP3 pulled down by NEK7, whereas p.R920Q increased 
the amount of protein pulled down; in contrast, NLRP3-
AID-associated mutation p.A352V, located in the NACHT 
domain, did not affect the interaction between NLRP3 and 
NEK7 (Fig. 3d), indicating an LRR-domain specific effect. 
Furthermore, when varying amounts of NEK7 were trans-
fected into HEK293T cells, the quantity of NEK7 pulled 
down by NLRP3 varied between the WT and p.R920Q 
protein. Although the amount of NEK7 pulled down at the 
lowest NEK7 concentration was comparable for both, the 
NLRP3-p.R920Q protein showed higher affinity for NEK7 at 
subsequent, higher amounts of transfected NEK7 (Fig. 3e), 
demonstrating a potential difference in protein–protein inter-
action kinetics depending on the ratio of these two proteins. 
Overall, this indicates that NLRP3/NEK7 interactions in 
the NLRP3 inflammasome containing the R920Q mutation 
are increased, which is likely to be facilitated by increased 
charge complementarity. These enhanced protein–protein 
interactions suggest that the increased IL-1β and IL-18 
release in patients’ monocytes may be due to a low threshold 
for NLRP3 inflammasome activation.
Transcriptomic Profile and Enriched Inflammatory 
Pathways in NLRP3‑R920Q Macrophages
As shown above, the patient’s monocytes exhibit dysregu-
lated inflammatory cytokine release indicative of an NLRP3-
AID. However, unlike previous reported cases [22], our 
patient responded poorly to anakinra, suggesting that other 
cellular processes may contribute to symptoms such as oro-
pharyngeal ulcers. We therefore carried out RNA-sequenc-
ing (RNA-seq) to investigate the transcriptomic profile of 
M0, M1 and M2 macrophages derived from CD14 + mono-
cytes, taken from the patient and two HCs, to investigate 
whether dysregulated macrophage polarisation was a con-
tributing factor, as observed in other autoinflammatory dis-
eases [28–30].
We initially conducted pairwise comparisons of the dif-
ferentially expressed genes (DEGs) between the patient’s 
M0, M1 and M2 macrophages and those from two HCs to 
investigate the global transcriptomic differences between 
the different cell types. Even considering the known tran-
scriptomic heterogeneity between donors [31], there was a 
marked difference in DEGs between cells taken from the 
patient and from the HCs. Grouping samples by genetic sim-
ilarity revealed common clusters of DEGs between differ-
ent macrophage subsets from both HCs, which were largely 
downregulated in the patient’s macrophages (Fig. 4a). Shared 
upregulated DEGs between the three cell subsets include 
the pseudogene HERC2P3, encoding the long non-coding 
RNA HERC2P3 which is related to ubiquitin-protein trans-
ferase activity [32], and PADI2, encoding peptidyl arginine 
deiminase 2, which catalyses the post-translational deimi-
nation of proteins [33] (Fig. 4b). HERC2P3 was in the top 
10 most significantly up or downregulated DEGs for all 3 
macrophage subsets (Fig. 4c). Further notable upregulated 
DEGs related to inflammatory responses include IL36B and 
IL36G in M1 macrophages, which encode the inflammatory 
cytokines IL-36β and IL-36γ, respectively, and IL17RB in 
M2 macrophages, which encodes IL-17 receptor B which is 
involved in IL-8 release (Fig. 4b).
We next analysed the DEGs in our patient’s macrophages 
compared to the HCs to identify common themes. Gene 
ontology (GO) analysis [34] showed significant enrichment 
of several GO terms associated with immune responses 
(Fig.  5a), although less notably in M0 macrophages 
(Fig. S5a). However, enriched terms in M2 macrophages 
included the BP terms ‘response to interferon-gamma’ 
(GO:0,034,341), ‘cellular response to interferon-gamma’ 
(GO:0,071,346) and ‘complement activation, classical 
pathway’ (GO:0,006,958) (Fig. 5a), indicating an altered 
inflammatory response in the patient’s M2 macrophages. 
Additional Kyoto Encyclopaedia of Genes and Genomes 
(KEGG) enrichment analysis [35] (Fig. 5b) showed that, 
although few KEGG terms were significantly enriched 
in M0 macrophages (Fig. S5b), terms related to cytokine 
signalling, particularly ‘NF-kappa B signalling pathway’ 
(hsa04064), ‘IL-17 signalling pathway’ (hsa04657) and 
‘Cytokine-cytokine receptor interaction’ (hsa04060) were 
enriched in M1 macrophages, the latter of which was also 
enriched in the patient’s M2 macrophages (Fig. 5b). We 
then generated a protein–protein interaction network using 
STRING version 11.0 [36] (Fig. 5c). While the nodes from 
the M0 DEGs were mostly independent (Fig. S5c), clusters 
of nodes seen in M1 and M2 macrophages showed promi-
nent involvement of the immune system and cytokine and 
chemokine signalling, with CXCL8, encoding IL-8, acting 
as a key component of many of the node clusters (Fig. 5c). 
Together, these analyses highlight a series of inflammatory 
pathways other than those directly regulated by the NLRP3 
inflammasome in this disease state.
Discussion
The NLRP3 inflammasome is the most widely studied 
of the inflammasomes, with over 150 currently validated 
pathogenic mutations [23]. Among these mutations, very 
few are in the LRR domain, and as a result, our knowledge 
of NLRP3-AIDs caused by such mutations is incomplete. 
We show here that the NLRP3-p.R920Q mutation causes 
enhanced interactions between NLRP3 and NEK7, leading 
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to increased NLRP3 inflammasome activity and affecting 
macrophage cytokine signalling.
Mutations in the LRR domain are associated with 
atypical or milder NLRP3-AIDs phenotypes [37], as seen 
here. Our case report adds to the small number of patients 
known to carry the NLRP3-p.R920Q mutation [5]. In these 
patients, the primary symptom was sensorineural hearing 
loss, whereas our patient did not report hearing difficul-
ties. Of the two families already described, one reported 
no further NLRP3-AID symptoms, whereas members of the 
second family reported autoinflammatory signs and symp-
toms including oral ulcers but without serologic signs of 
inflammation. This disparity in symptoms shows that the 
p.R920Q mutation can be associated with different disease 
severity in different families, a phenomenon observed with 
other NLRP3 mutations [38]. However, arguably, the larg-
est difference between our patient and previously reported 
families was response to treatment. Anakinra was effective 
Fig. 4  Macrophage transcriptomic profiles differ between patient’s 
and HCs. a Pairwise differential expression between HC and patient’s 
samples for M0, M1 and M2 macrophages. Heatmaps show the DEGs 
(q < 0.05), and the colour scale represents the Log2(FPKM) values. 
Genes were grouped by Euclidean clustering in rows. b DEGs in M0, 
M1 and M2 macrophages are shown as Log2-fold change; upregu-
lated genes are shown in red and downregulated genes in blue. c Vol-
cano plots showing the Log2-fold change and p value for the DEGs 
in each cell type; DEGs (p > 0.05) are shown in blue, if significantly 
downregulated, and red if significantly upregulated
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in treating hearing loss and improving the symptoms of auto-
inflammation in both published families [5]; in contrast, our 
patient only partially responded to anakinra, which improved 
her fevers and partly helped with headaches and arthral-
gia but did not improve mucosal ulceration. Oral ulcers 
were improved; however, following addition of the PDE4 
Fig. 5  Gene set enrichment analyses reinforce a role for cytokine sig-
nalling pathways in the disease state. a Gene ontology (GO) enrich-
ment analysis of DEGs between the patient’s and HC macrophages 
for M1 and M2 macrophages containing 3 sub-ontologies: biological 
process (BP), cellular component (CC) and molecular function (MF). 
The 15 most significant GO terms are shown (p < 0.001). Enrichment 
analysis was carried out using DAVID bioinformatics online resource 
6.8. b Kyoto encyclopaedia of genes and genomes (KEGG) analy-
sis showing biological function and pathway enrichment of DEGs 
between the patient and HCs for M1 and M2 macrophages (p < 0.01). 
c Network of predicted protein–protein interactions derived from the 
list of DEGs between the patient’s and HC macrophages, as deter-
mined by STRING analysis. Lines between nodes depict known 
interactions from curated databases (light blue), experimentally deter-
mined interactions (pink), co-expressed proteins (black) and homolo-
gous proteins (violet)
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inhibitor, apremilast, to her treatment regimen, suggesting 
that signalling pathways other than those directly mediated 
by the NLRP3 inflammasome were dysregulated. RNA-seq 
showed that the NF-кB signalling pathway was enriched in 
the patient’s M1 macrophages, and since apremilast acts via 
a NF-кB-dependent mechanism to reduce levels of inflam-
matory cytokines such as TNF [39], this may provide an 
explanation for the efficacy of this treatment. The IL-17 
signalling pathway was also enriched in M1 macrophages, 
which is notable because NLRP3 inflammasome activation 
and IL-1β release have been linked to enhanced inflamma-
tory Th17 cell responses in diseases including ankylosing 
spondylitis [40], inflammatory skin diseases including 
hidradenitis suppurativa [41, 42], rheumatoid arthritis [43] 
and obliterative bronchiolitis [44]. A MWS-related NLRP3 
mutation also caused spontaneous skin inflammation in mice 
due to increased IL-1β production and consequent Th17 cell 
predominance [45]. As such, enrichment of IL-17 signal-
ling in our patient’s M1 macrophages may contribute to 
the inflammatory phenotype. It may also partly explain the 
efficacy of apremilast, as this agent reduces inflammatory 
cytokine release and increases anti-inflammatory cytokine 
production in response to IL-17 stimulation in psoriasis 
[46–48], and IL-17A is a biomarker of apremilast efficacy 
in psoriasis [49]. CXCL8, encoding the neutrophil chem-
oattractant IL-8, was also upregulated in the patient’s M1 
and M2 macrophages. Aberrant regulation of IL-8 has been 
implicated in numerous inflammatory diseases [50–53], 
including mucosal tissues, which may partly explain the 
mucosal ulceration observed here.
The study which first reported pathogenic cases of this 
mutation also investigated the cochlea of mice and iden-
tified tissue-resident macrophage-like cells which secrete 
IL-1β in response to LPS and ATP stimulation, which may 
mediate local autoinflammation in the cochlea [5]. In this 
report, we have expanded on this by elucidating a molecu-
lar mechanism of how the p.R920Q mutation leads to an 
atypical phenotype. Previously reported NLRP3 mutations 
have been shown to affect interactions between NLRP3 and 
its endogenous regulator NEK7 [10, 27]; the p.G755R and 
p.G755A mutations, which cause CINCA, increase the affin-
ity between NLRP3 and NEK7 [24, 25], while the hypomor-
phic NLRP3 missense mutation p.D946G binds with less 
avidity to NEK7 than to the WT protein [26]. The p.R920Q 
mutation increases NLRP3 interactions with NEK7, which 
was predicted by our in silico interrogation of the protein 
structure to be due to the reduction in positive charge density 
at the NLRP3/NEK7 interface when the positively charged 
arginine residue was substituted for an uncharged glutamine.
The function of the LRR domain remains unclear. The 
recently determined cryo-EM structure of NLRP3 in com-
plex with NEK7 suggests that the LRR and NACHT domains 
of NLRP3 are important in protein–protein interactions with 
NEK7 [10], and the second of the two major isoforms, iden-
tified in humans lacking exon 5 resulting in a truncated LRR 
domain, exhibits a loss of activity due to a loss of NLRP3/
NEK7 interactions [54]. However, other studies have shown 
that NLRP3 protein lacking the LRR domain can be acti-
vated by the canonical inflammasome pathway [4, 55, 56]. 
Two recent preprint studies reporting cryo-EM structures of 
full-length NLRP3 in its native form indicate that interac-
tions between LRR domains are important for the formation 
of its endogenous ‘ring cage’ structure [57, 58]. In Hoch-
heiser et al., residue R920 is proposed to lie within a concave 
site in the LRR domain which forms contacts between two 
opposing LRRs; this LRR-LRR interaction is mediated by 
an acidic loop extending from an LRR transition segment, 
suggesting that the p.R920Q mutation may affect electro-
static interactions between this loop and the LRR domain 
in the inactive form. Overall, our observations add to the 
LRR story, supporting the idea that missense mutations in 
the LRR domain can play a crucial role in NLRP3 inflam-
masome function.
Despite the increased understanding with regards to the 
structural basis of NLRP3 inflammasome function, efforts in 
understanding the structure–function relationship of NLRP3 
are frequently centred on the central NACHT domain. This 
is due to a combination of factors, including the majority 
of the NLRP3-AID-related mutations being found in this 
region [59] and because many NLRP3 inhibitors bind to 
this domain [60, 61]. The most well-studied pharmacologi-
cal NLRP3 inflammasome inhibitor, MCC950, has been 
shown to target NLRP3 in the region of the Walker B motif 
of the NACHT domain [60]. As such, previous studies uti-
lising a structure-based approach to investigate small mol-
ecule inhibitors of the NLRP3 inflammasome, using either 
a homology model of NLRP3 produced using the NLRC4 
crystal structure [62] or the NLRP3/NEK7 cryo-EM struc-
ture [10], have targeted the search of druggable binding sites 
close to the Walker B region [63, 64]. However, the NLRP3 
inflammasome inhibitor 3,4-Methylenedioxy-β-nitrostyrene 
(MNS) binds to the NACHT and LRR domains [65], demon-
strating that there is potential for small molecule inhibitors 
targeting domains other than NACHT, particularly in disease 
conditions involving LRR domain mutations.
Due to a scarcity of patient blood samples resulting from 
a combination of her pregnancy and COVID-19 restric-
tions in hospitals, the present study primarily investigated 
the effects of the p.R920Q variant in circulating myeloid 
cells, where the NLRP3 inflammasome is predominantly 
expressed (Guarda et al. 2011). However, a future avenue 
of investigation would be to explore the effect of this muta-
tion in cells such as neutrophils, particularly as neutrophil-
specific Nlrp3 mutations have recently been shown to pro-
mote the development of NLRP3-AIDs in mice [66], and 
PDE4 inhibitors such as apremilast can inhibit neutrophil 
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extracellular trap formation [67, 68]. This may also offer 
further insights into the kinetics of the p.R920Q mutation, 
in addition to the immunoprecipitation studies carried out 
above.
In summary, we have shown that the rare NLRP3-p.
R920Q mutation is associated with an atypical presenta-
tion. This is likely connected to enhanced NLRP3-NEK7 
interactions, which lead to a lower activation threshold for 
the NLRP3 inflammasome, in addition to involvement of 
different convergent pathways. Our results highlight the 
importance of investigating alternative pathways involved 
in disease states and outline a potential course of treatment 
for atypical NLRP3-AIDs patients.
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